等待开盘 11-17 09:30:00 美东时间
-0.355
-1.54%
Structure Therapeutics reported financial results for Q3 2026 and provided updates on its obesity portfolio. The company is advancing aleniglipron, an oral GLP-1 receptor agonist, with Phase 3 ACCOMPLISH trials enrolling patients for chronic weight management, targeting topline data in H2 2028. Additional aleniglipron data from body composition, T2DM, and SWITCH studies are expected in Q4 2026. ACCG-2671, an oral amylin receptor agonist, showed a...
11-09 21:05